Sodium and chloride channelopathies with myositis: Coincidence or connection?

Muscle and Nerve

Volumn 44, Issue 2, 2011, Pages 283-288

  Matthews, Emma ^a   Miller, JAMES A L ^b   MacLeod, Malcolm R ^c,d   Ironside, James ^e   Ambler, Gareth ^f   Labrum, Robin ^g   Sud, Richa ^g   Holton, Janice L ^a   Hanna, Michael G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c Stirling Royal Infirmary   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Channelopathy; Histopathology; Myositis; Neuromuscular; Treatment

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; CYCLOSPORIN; HYDROXYUREA; IMATINIB; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE; SALBUTAMOL;

ADULT; AGED; ARTICLE; CASE REPORT; CD3+ T LYMPHOCYTE; CHLORIDE CHANNELOPATHY; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DNA SEQUENCE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTROMYOGRAM; FASCICULATION; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; MUSCLE BIOPSY; MUSCLE CHANNELOPATHY; MUSCLE CRAMP; MUTATIONAL ANALYSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIODIC PARALYSIS; POLYMERASE CHAIN REACTION; POLYMYOSITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOLEMMA; SODIUM CHANNELOPATHY; THOMSEN DISEASE; TREATMENT RESPONSE;

ADULT; AGED, 80 AND OVER; CHANNELOPATHIES; CHLORIDE CHANNELS; FEMALE; HUMANS; MALE; MUSCLE WEAKNESS; MUSCLES; MYOSITIS; SODIUM CHANNELS;

EID: 79960538399     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22120     Document Type: Article

References (11)

1. Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes: progress over the past decade. Muscle Nerve 2003;27:4-25.
2. Ohno K, Quiram PA, Milone M, Wang HL, Harper MC, Pruitt JN II, et al. Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene: identification and functional characterization of six new mutations. Hum Mol Genet 1997;6:753-766.
3. Sieb JP, Kraner S, Schrank B, Reitter B, Goebel TH, Tzartos SJ, et al. Severe congenital myasthenic syndrome due to homozygosity of the 1293insG epsilon-acetylcholine receptor subunit mutation. Ann Neurol 2000;48:379-383.
4. Edgeworth, H. The effect of ephedrine in the treatment of myasthenia gravis: second report. J Am Med 1933;100:1401.
5. Patten BM. Myasthenia gravis: review of diagnosis and management. Muscle Nerve 1978;1:190-205.
6. Bestue-Cardiel M, Sáenz de Cabezón-Alvarez A, Capablo-Liesa JL, López-Pisón J, Peña-Segura JL, Martin-Martinez J, et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 2005;65:144-146,
7. Palace J, Lashley D, Newsom-Davis J, Cossins J, Maxwell S, Kennett R, et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain 2007;130:1507-1515.
8. Cereda C, Kuntzer T. The potential use of ephedrine in Lambert-Eaton myasthenic syndrome. Clinical and electrophysiological evaluation. J Neurol 2008;255:1259-1260.
9. Sieb JP, Engel AG. Ephedrine: effects on neuromuscular transmission. Brain Res 1993;623:167-171.
10. Milone M, Engel AG. Block of the endplate acetylcholine receptor channel by the sympathomimetic agents ephedrine, pseudoephedrine, and albuterol. Brain Res 1996;740:346-352.
11. Molenaar PC, Biewenga JE, van Kempen GT, De Priester JA. Effect of ephedrine on muscle weakness in a model of myasthenia gravis inrats. Neuropharmacology 1993;32:373-376.